Analyzing cancer treatment outcomes using a new statistical method
Survival Data Analysis using general censoring-free incident rate
['FUNDING_R01'] · DANA-FARBER CANCER INST · NIH-11036324
This study is testing a new way to better understand how cancer treatments work, so patients and doctors can make smarter choices about care.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11036324 on ClinicalTrials.gov |
What this research studies
This research focuses on improving how we analyze the effectiveness of cancer treatments by developing a new statistical method that provides clearer insights into treatment risks and benefits. Traditionally, methods like the log-rank test have been used, but they often lack the detailed information needed for patients and clinicians to make informed decisions. The new approach, called the average hazard, offers a more interpretable measure of treatment effects over time, which could help guide patient-centered treatment choices. By utilizing this innovative method, the research aims to enhance the understanding of how different cancer therapies impact patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients who are considering or currently undergoing treatment and are seeking detailed information about the risks and benefits of their options.
Not a fit: Patients who are not currently undergoing cancer treatment or those with conditions unrelated to cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more informed treatment decisions for cancer patients, improving their overall care and outcomes.
How similar studies have performed: While traditional methods have been widely used, this new approach represents a novel advancement in cancer treatment analysis, aiming to fill gaps left by previous methodologies.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: UNO, HAJIME — DANA-FARBER CANCER INST
- Study coordinator: UNO, HAJIME
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy, cancer immunotherapy, cancer therapy